Abstract
Kaposi sarcoma (KS) may rarely occur in transplant recipients through primary human herpesvirus-8 (HHV-8) infection from a seropositive donor. This report describes a patient who developed hepatic KS after receiving a split liver transplant from an HHV-8-positive donor. The recipient was treated with liposomal doxorubicin after reduction in immunosuppression led to acute cellular rejection. This treatment achieved regression of KS while preserving allograft function, demonstrating a successful therapeutic strategy for this malignancy.
Keywords:
human herpesvirus-8; liver transplant; post-transplant Kaposi Sarcoma.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
-
Allografts / diagnostic imaging
-
Allografts / pathology
-
Allografts / virology
-
Doxorubicin / analogs & derivatives*
-
Doxorubicin / therapeutic use
-
Female
-
Herpesviridae Infections / diagnosis
-
Herpesviridae Infections / pathology
-
Herpesviridae Infections / transmission*
-
Herpesviridae Infections / virology
-
Herpesvirus 8, Human / isolation & purification
-
Humans
-
Liver / diagnostic imaging
-
Liver / pathology
-
Liver / virology
-
Liver Neoplasms / diagnosis
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / pathology
-
Liver Neoplasms / virology
-
Liver Transplantation / adverse effects*
-
Magnetic Resonance Imaging
-
Male
-
Middle Aged
-
Polyethylene Glycols / therapeutic use
-
Sarcoma, Kaposi / diagnosis
-
Sarcoma, Kaposi / drug therapy*
-
Sarcoma, Kaposi / pathology
-
Sarcoma, Kaposi / virology
-
Tissue Donors
-
Transplantation, Homologous / adverse effects
-
Treatment Outcome
-
Young Adult
Substances
-
liposomal doxorubicin
-
Polyethylene Glycols
-
Doxorubicin